Tandem Diabetes Care
TNDM
42 hedge funds and large institutions have $3.92M invested in Tandem Diabetes Care in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 17 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
13.25% more ownership
Funds ownership: 3.16% → 16.41% (+13%)
9% less funds holding
Funds holding: 46 → 42 (-4)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
86% less capital invested
Capital invested by funds: $28M → $3.92M (-$24.1M)
Top Buyers
Top Sellers
TNDM Hedge Fund Activity: Q4 2017 in Review
42 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q4 2017, worth a combined $3.92M — down 86% from $28M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TNDM and 13 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 13 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $437K. The largest seller was Russell Investments Group, exiting entirely with an estimated $482K sold.
- 42 institutional investors held Tandem Diabetes Care (TNDM) as of Q4 2017, down from 46 in Q3 2017.
- Funds reported $3.92M of Tandem Diabetes Care stock for Q4 2017, down 86% quarter-over-quarter.
- 13 funds opened new Tandem Diabetes Care positions in Q4 2017 and 17 closed out, a net change of -4 holders.
- The largest Tandem Diabetes Care buyer in Q4 2017 was Alyeska Investment Group, an estimated $437K added.
- The largest Tandem Diabetes Care seller in Q4 2017 was Russell Investments Group, an estimated $482K sold.
Based on aggregated 13F filings for Q4 2017.